TAFopathies Result from Derangements in Transcriptional Control of Metabolism

NIH RePORTER · NIH · F31 · $31,970 · view on reporter.nih.gov ↗

Abstract

Project Summary Intellectual disability is a disabling neurodevelopmental disorder that affects 2-3% of the general population. Often times, these intellectual disabilities are accompanied by additional developmental abnormalities. These syndromic forms of intellectual disability frequently have a genetic basis. Recent studies have identified a subset of intellectual disability patients with pathogenic variants in key components of the TATA-binding protein associated factors (TAFs). These patients also have craniofacial defects and congenital heart disease. This syndrome has been termed as a TAFopathy and includes mutations in TATA binding protein (TBP), TAF1, TAF2, and TAF6. Through a forward genetic screen, we have recovered a lethal nonsense mutation in TAF5. Mutant embryos have craniofacial hypoplasia, ventricular hypoplasia, and heart failure at 96 hours post fertilization. CRISPR/Cas9 mediated gene editing revealed that this phenotype was recapitulated in TAF1 KO and TAF5 KO embryos. TAF5 KOs show significant metabolic dysfunction that may precede the anatomical defects observed at 96 hours post fertilization. Together, these findings support a regulatory role for TAFs in coordinating transcriptional activation of metabolic programming during embryogenesis. The TAFs form the general transcription factor TFIID, which recruits RNA Polymerase II to form the preinitation complex at sites of transcription. Studies have shown that individual TAFs are not necessary for general transcription. Other studies have identified functional domains of TAF1 that activate transcription through interactions with TBP and enhancer elements that are sufficient to recruit RNA Polymerase II to sites of transcription. In conjunction with our data showing metabolic dysfunction, we hypothesize that TAFs regulate metabolic programs by linking enhancers and promoters of metabolic genes through TFIID assembly. Our current efforts are focused towards completing our phenotypic characterization of TAF1 KOs and TAF5 KOs with respect to craniofacial- and neuro-development. We plan to use innovative and cutting-edge techniques, including x-ray microscopy, RNA- Scope in situ hybridization, mitochondrial respiration assays, ChIP-seq, and Hi-C to achieve this goal. The data obtained will help us elucidate basic disease mechanisms of TAFopathy. These findings would also indicate a secondary function for general transcription factors to regulate metabolic programming during embryogenesis. .

Key facts

NIH application ID
10314285
Project number
1F31HD106710-01
Recipient
WASHINGTON UNIVERSITY
Principal Investigator
Jamison Leid
Activity code
F31
Funding institute
NIH
Fiscal year
2021
Award amount
$31,970
Award type
1
Project period
2021-09-01 → 2023-08-31